Dynamics of epigenetic age following hematopoietic stem cell transplantation

Haematologica

Volumn 102, Issue 8, 2017, Pages e321-e323

  Stölzel, Friedrich ^a,b   Brosch, Mario ^a   Horvath, Steve ^c   Kramer, Michael ^a   Thiede, Christian ^a,b,d   Von Bonin, Malte ^a,b,d   Ammerpohl, Ole ^e   Middeke, Moritz ^a   Schetelig, Johannes ^a,f   Ehninger, Gerhard ^a,b,d   Hampe, Jochen ^a   Bornhäuser, Martin ^a,b,d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b German Consortium for Translational Cancer Research (DKTK)   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f DKMS Nabelschnurblutbank   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DRB1 ANTIGEN;

ACUTE MYELOID LEUKEMIA; AGING; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LETTER; PROPHYLAXIS; REJUVENATION; TELOMERE LENGTH; ALLOTRANSPLANTATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

AGING; EPIGENOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 85026772096     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.160481     Document Type: Letter

References (15)

1. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579-590.
2. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-562.
3. Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007; 13(5):601-607.
4. Kollman C, Spellman SR, Zhang MJ, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hema- tologic malignancy. Blood. 2016;127(2):260-267.
5. Notaro R, Cimmino A, Tabarini D, Rotoli B, Luzzatto L. In vivo telomere dynamics of human hematopoietic stem cells. Proc Natl Acad Sci USA. 1997;94(25):13782-13785.
6. Rufer N, Brummendorf TH, Chapuis B, Helg C, Lansdorp PM, Roosnek E. Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood. 2001;97(2):575-577.
7. Weidner CI, Ziegler P, Hahn M, et al. Epigenetic aging upon allogeneic transplantation: the hematopoietic niche does not affect age-asso-ciated DNA methylation. Leukemia. 2015;29(4):985-988.
8. Lowe D, Horvath S, Raj K. Epigenetic clock analyses of cellular senescence and ageing. Oncotarget. 2016;7(8):8524-8531.
9. Thornley I, Sutherland R, Wynn R, et al. Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood. 2002;99(7):2387-2396.
10. Wynn R, Thornley I, Freedman M, Saunders EF. Telomere shortening in leucocyte subsets of long-term survivors of allogeneic bone marrow transplantation. Br J Haematol. 1999;105(4):997-1001.
11. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 1998;351(9097):178-181.
12. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.
13. Marioni RE, Shah S, McRae AF, et al. DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol. 2015;16:25.
14. Perna L, Zhang Y, Mons U, Holleczek B, Saum KU, Brenner H. Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort. Clin Epigenetics. 2016;8:64.
15. Szyper-Kravitz M, Uziel O, Shapiro H, et al. Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34+ haematopoietic cells and may prevent telomere attrition after chemotherapy. Br J Haematol. 2003;120(2):329-336.